Categories: HealthcareNews

Mendel and UMass Amherst Unveil Groundbreaking Research on AI-driven Hallucination Detection in Healthcare

Innovative framework developed to ensure the accuracy and reliability of AI-generated medical summaries.

SAN JOSE, Calif. and AMHERST, Mass., Aug. 6, 2024 /PRNewswire/ — Mendel, a leader in healthcare AI, and the University of Massachusetts Amherst (UMass Amherst) have jointly published pioneering research addressing the critical issue of faithfulness hallucinations in AI-generated medical summaries. This collaborative effort marks a significant advancement in ensuring the safety and reliability of AI applications in healthcare settings.

Research Overview

In recent years, large language models (LLMs) such as GPT-4o and Llama-3 have shown remarkable capabilities in generating medical summaries. However, the risk of hallucinations—where AI outputs include false or misleading information—remains a significant concern. This study aimed to systematically detect and categorize these hallucinations to improve the trustworthiness of AI in clinical contexts.

The research team developed a robust detection framework, categorizing hallucinations into five types. A pilot study of 100 summaries from GPT-4o and Llama-3 models revealed that GPT-4o produced longer summaries (>500 words) and often made bold, two-step reasoning statements, leading to hallucinations. Llama-3 hallucinated less by avoiding extensive inferences, but it’s summaries were of lower quality. Below is a table summarizing the inconsistencies identified in both models:

“Our findings highlight the critical risks posed by hallucinations in AI-generated medical summaries,” said Andrew McCallum, Distinguished Professor of Computer Science, University of Massachusetts Amherst. “Ensuring the accuracy of these models is paramount to preventing potential misdiagnoses and inappropriate treatments in healthcare.”

The study also explored automated detection methods to mitigate the high costs and time associated with human annotations. The Hypercube system, leveraging medical knowledge bases, symbolic reasoning and NLP, played a crucial role in detecting hallucinations. It provided a comprehensive representation of patient documents, aiding in the initial detection step before human expert review.

“We are committed to continually enhancing Hypercube’s capabilities. The future of healthcare AI depends on reliable, accurate tools, and Hypercube’s evolving features, including real-time data processing and adaptive learning algorithms, will keep it at the forefront of clinical innovation,” said Dr. Wael Salloum, Chief Scientific Officer of Mendel AI.

Future Prospects

As AI continues to integrate into healthcare, addressing hallucinations in LLM outputs will be vital. Future research will focus on refining detection frameworks and exploring more advanced automated systems like Hypercube to ensure the highest levels of accuracy and reliability in AI-generated medical content. Hypercube’s real-time data processing and adaptive learning algorithms will be essential in maintaining its position at the forefront of clinical innovation.

Accepted Paper

Mendel’s work on Hypercube in detecting hallucinations is recognized by the academic community. The research paper, “Faithfulness Hallucination Detection in Healthcare AI,” is accepted for the KDD AI conference, August 2024. It details the methodologies and technologies underpinning Hypercube’s success.

For more information about the Hypercube platform try the Hypercube demo.

About Mendel

Mendel AI supercharges clinical data workflows by coupling large language models with a proprietary clinical hypergraph, delivering scalable clinical reasoning without hallucinations and ensuring 100% explainability. Headquartered in San Jose, California, Mendel is backed by blue-chip investors, including Oak HC/FT and DCM. For more information, visit Mendel or contact marketing@mendel.ai.

About UMass Amherst

UMass Amherst, the flagship campus of the University of Massachusetts system, is a nationally ranked public research university known for its excellence in teaching, research, and community engagement. The university fosters innovation and collaboration across a wide range of disciplines. For more information, visit UMass Amherst.

Press Contact: Jessica McNellis, Gale Strategies (Jessica@GaleStrategies.com)

View original content:https://www.prnewswire.com/news-releases/mendel-and-umass-amherst-unveil-groundbreaking-research-on-ai-driven-hallucination-detection-in-healthcare-302214850.html

SOURCE Mendel

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

21 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

21 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

21 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

21 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

21 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

21 hours ago